Ticker > Company >

Strides Pharma Scien share price

Strides Pharma Science Ltd.

NSE: STAR BSE: 532531 SECTOR: Pharmaceuticals & Drugs  89k   133   31

883.40
+30.15 (3.53%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 900

Today's Low

₹ 840.85

52 Week High

₹ 1675.25

52 Week Low

₹ 530.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

8141.65 Cr.

Enterprise Value

9624 Cr.

No. of Shares

9.22 Cr.

P/E

137.63

P/B

2.55

Face Value

₹ 10

Div. Yield

0.45 %

Book Value (TTM)

₹  346.42

CASH

111.83 Cr.

DEBT

1594.18 Cr.

Promoter Holding

28.3 %

EPS (TTM)

₹  6.42

Sales Growth

16.11%

ROE

1.87 %

ROCE

4.77%

Profit Growth

1298.78 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.11%
3 Year5.05%
5 Year6.97%

Profit Growth

1 Year1298.78%
3 Year-5.76%
5 Year-9.91%

ROE%

1 Year1.87%
3 Year2.48%
5 Year2.73%

ROCE %

1 Year4.77%
3 Year2.84%
5 Year3.58%

Debt/Equity

0.4481

Price to Cash Flow

-227.7

Interest Cover Ratio

1.4146

CFO/PAT (5 Yr. Avg.)

0.765681390851817

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 28.30 51.98
Dec 2024 26.82 54.25
Sep 2024 25.84 49.17
Jun 2024 25.86 64.65
Mar 2024 25.88 72.70
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.107990543834937.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.44755687213534.

 Limitations

  • The company has shown a poor profit growth of -5.75660412141952% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.04701712407989% for the Past 3 years.
  • Company has a poor ROE of 2.47698991797854% over the past 3 years.
  • Company has a poor ROCE of 2.83846342205997% over the past 3 years
  • Company has high debtor days of 238.695.
  • Company has negative cash flow from operations of -35.756.
  • Tax rate is low at 5.9321.
  • The company is trading at a high PE of 137.63.
  • The company is trading at a high EV/EBITDA of 30.0276.
  • Promoter pledging is high as 51.98%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 602.95 554.75 609.96 550.92 555.96
Total Expenditure 491.53 493.72 546.93 476.82 488.03
Operating Profit 111.42 61.03 63.03 74.1 67.93
Other Income 25.65 11.83 23.55 2.43 12.12
Interest 39.05 46.88 50.15 34.21 29.36
Depreciation 21.92 20.32 21.98 20.92 22.37
Exceptional Items -0.07 0 -0.01 -0.02 0
Profit Before Tax 76.02 5.66 14.43 21.38 28.32
Tax -2.83 1.75 -0.88 6.44 12.2
Profit After Tax 78.84 3.92 15.31 14.94 16.13
Adjusted EPS (Rs) 8.58 0.43 1.66 1.62 1.75

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1691.93 1857.57 1979 1854.5 2153.26
Total Expenditure 1487.48 1698.34 1902.37 1771.77 1905.95
Operating Profit 204.46 159.23 76.63 82.72 247.31
Other Income 93.07 117.09 123.49 99.82 80.28
Interest 66.84 65.34 74.24 138.68 167.93
Depreciation 94.24 99.34 104.37 93.62 84.67
Exceptional Items 0 0 0 -15 -5.37
Profit Before Tax 136.45 111.64 21.51 -64.76 69.62
Tax 16.17 33.4 -158.68 -69.44 4.13
Net Profit 120.28 78.24 180.19 4.68 65.49
Adjusted EPS (Rs.) 13.43 8.72 20.07 0.52 7.13

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 89.57 89.68 89.79 90.3 91.9
Total Reserves 3069.22 3158.38 3316.89 3364.75 3469.22
Borrowings 0 147.54 124.7 284.74 196.99
Other N/C liabilities -37.31 159.89 -16.42 -12.12 -7.12
Current liabilities 1454.95 1590.64 1841.32 1796.83 1995.3
Total Liabilities 4576.42 5146.12 5356.28 5524.5 5746.29
Assets
Net Block 578.35 576.66 604.09 584.3 544.58
Capital WIP 89.47 81.36 30.45 15.79 57.71
Intangible WIP 22.78 29.31 25.26 39.59 36.29
Investments 2170.55 2394.65 2399.76 2491.77 2498.34
Loans & Advances 237.42 247.33 304.95 245.47 174.39
Other N/C Assets 83.82 72.96 16.51 21.18 19.13
Current Assets 1394.03 1743.86 1975.25 2126.4 2415.86
Total Assets 4576.42 5146.12 5356.28 5524.5 5746.29
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 136.45 111.64 21.51 -64.76 69.62
Adjustment 130.28 114.15 75.17 172.87 215.99
Changes in Assets & Liabilities -96.91 -109.81 -400.77 33.81 -375.08
Tax Paid -32.18 166.79 21.41 99.82 53.71
Operating Cash Flow 137.64 282.76 -282.69 241.74 -35.76
Investing Cash Flow 62.83 -275.64 18.78 -182.58 -61.27
Financing Cash Flow -203.56 -48.64 250.73 10.82 107.62
Net Cash Flow -3.09 -41.52 -13.18 69.98 10.6

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 25.88 25.86 25.84 26.82 28.30
aditya arun kumar 0.06 0.06 0.06 0.06 0.06
agraganya private trust (... - - - 0.33 0.33
ambemata securities (vima... - - - - 0.26
anuradha k r 0.01 0.01 0.01 0.01 0.01
arun kumar pillai 2.11 2.11 2.11 2.13 2.24
hemalatha pillai 0.07 0.07 0.07 0.07 0.07
k r lakshmi 0.14 0.14 0.14 0.14 0.14
k r ravishankar 1.37 1.37 1.37 1.36 1.36
karuna business solutions... 3.51 3.51 3.51 3.50 3.50
padmakumar karunakaran pi... 0.20 0.20 0.20 0.20 0.20
pronomz ventures llp 17.18 17.18 17.17 18.22 19.58
rajitha gopalakrishnan 0.07 0.07 0.07 0.07 0.07
sajitha pillai 0.10 0.10 0.10 0.10 0.10
shasun enterprises llp (f... - - - 0.17 0.17
vineetha mohanakumar pill... 0.21 0.21 0.21 0.21 0.21
ambemata securities 0.26 0.26 0.26 0.26 -
agraganya private trust 0.33 0.33 0.33 - -
shasun enterprises llp 0.26 0.24 0.24 - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 74.12 74.14 74.16 73.18 71.70
authum investment and inf... - - - - 1.11
axis mutual fund trustee ... - - - 1.54 1.24
bnp paribas financial mar... - - 1.12 1.33 1.31
investor education and pr... - - - 0.15 0.15
morgan stanley asia (sing... 1.08 1.26 1.35 1.62 2.02
mukul mahavir agrawal 1.63 1.63 1.52 1.16 1.16
oman india joint investme... 1.10 1.10 1.10 1.10 1.10
quant mutual fund - quant... - - 5.41 5.40 5.40
route one fund i, l.p. 2.17 2.17 2.17 2.17 2.17
route one offshore master... 5.06 5.06 5.06 5.05 5.05
satpal khattar 1.70 1.70 1.70 1.60 1.60
sbi life insurance co. lt... - 1.26 2.19 2.23 2.09
vanguard total internatio... - - - - 1.03
aditya birla sunlife trus... - - - 1.43 -
amansa holdings private l... 4.15 4.15 3.87 1.73 -
max life insurance compan... - - 1.32 1.04 -
aditya birla sun life tru... - - 3.35 - -
investor education and pr... 0.15 0.15 0.15 - -
life insurance corporatio... 3.17 2.81 1.91 - -
aditya birla sun life tru... 5.03 4.94 - - -
bnp paribas financial mar... 1.16 1.08 - - -
max life insurance co ltd... - 1.64 - - -
quant mutual fund 5.42 5.42 - - -
max life insurance compan... 1.64 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit FITCH
Credit ICRA
TYPE AGENCY ACTION
Research Report By:
Research HDFC Securities
Research Geojit BNP Paribas

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY25
Concall Q4FY24
Concall Q3FY24
Concall Q2FY24
Concall Q2FY21
Concall Q2FY20
Concall Q1FY25
Concall Q1FY24
Concall Q1FY21
TYPE QUARTER ACTION
Presentation Q4FY23
Presentation Q3FY24
Presentation Q2FY19
Presentation Q1FY25
Presentation Q1FY21

Company News

Strides Pharma Scien Stock Price Analysis and Quick Research Report. Is Strides Pharma Scien an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Strides Pharma Scien and its performance over the period of time. Strides Pharma Scien stock price today is Rs 882.45.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Strides Pharma Scien cash from the operating activity was Rs -35.756 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Strides Pharma Scien has a Debt to Equity ratio of 0.4481 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Strides Pharma Scien , the EPS growth was 1274.4069 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Strides Pharma Scien has OPM of 11.4852470070935 % which is a bad sign for profitability.
     
  • ROE: Strides Pharma Scien have a poor ROE of 1.8729 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Strides Pharma Scien is Rs 882.45. One can use valuation calculators of ticker to know if Strides Pharma Scien share price is undervalued or overvalued.
Last Updated on:
Brief about Strides Pharma Scien
X